InMed Launches Study on Cannabis-Based COPD Therapy

InMed Pharmaceuticals is expanding its product line by initiating studies on a potential treatment for chronic obstructive pulmonary disease (COPD). The clinical stage company specializes in the development of therapeutic options based on cannabis, and will launch a new program designed to discover and assess cannabinoid compounds able to treat COPD.

InMed announced that its new program focused on finding cannabis-based treatments for COPD has already initiated its first drug discovery efforts and preclinical tests in partnership with investigators from the Department of Anesthesiology, Pharmacology & Therapeutics at the University of British Columbia in Vancouver, Canada.

“We’re excited to explore avenues to further expand InMed’s pipeline with the addition of new program targeting COPD, the third leading cause of death in the United States,” said InMed’s president and CEO Craig Schneider. COPD is a chronic pulmonary disease that affects more than 50 million people worldwide and progressively degrades the ability to breathe, increasing mucus production, cough and chest tightness.

Previous research has suggested the effectiveness of cannabinoid compounds in improving COPD symptoms, since the most significant active ingredient in cannabis, THC, has the ability to provoke short-term bronchodilation. In addition, cannabinoids may also disable the proliferation and activation of T-cells and have anti-inflammatory proprieties.

“Current treatments for COPD are complex and ineffective and there is currently no cure available. It is well known that cannabinoids exhibit bronchodilatory, immunosuppressive, and anti-inflammatory properties and thus cannabinoid-based therapy may offer safer and more effective treatment options for COPD,” explained the chief scientific officer at the company, Sazzad Hossain.

The initial research is being conducted by InMed investigator Dmitri Pechkovsky, who is working in collaboration with Pascal Bernatchez in his lab at the University of British Columbia. With a PhD in Immunology and Allergy from Minsk State Medical Institute in Belarus and post-doctoral training from the Research Center Borstel-Leibniz Center for Medicine and Biosciences (FZB), Luebeck University, and University of Freiburg in Germany, Pechkovsky has proven experience in studying pulmonary diseases, such as COPD, idiopathic pulmonary fibrosis and asthma.

3 comments

Oh stage lll copd Dx 12/2014, just 20% lung function. Sounds 2/2015 I use No puffers, No oxygen, No steroids . How? High thc feco oil is all I use. For three plus years. Get there is better news I. Tetrahydrocannbivarin, ThcV . Waiting for that. But indeed my lungs have been restored by cannabinoids. I am three plus years of proof.
Have you thcv???

Oh stage lll copd Dx 12/2014, just 20% lung function. Sounds 2/2015 I use No puffers, No oxygen, No steroids . How? High thc feco oil is all I use. For three plus years. Get there is better news I. Tetrahydrocannbivarin, ThcV . Waiting for that. But indeed my lungs have been restored by cannabinoids. I am three plus years of proof.
Have you thcv???

Disclaimer:

Lung Disease News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. We never use your cookies for creepy ad retargeting that follows you around the web. OkRead more